Navigation Links
Brigham and Women's Hospital Researchers Demonstrate a More Direct Delivery of Cancer Drugs to Tumors
Date:4/20/2009

An interdisciplinary team of researchers at Brigham and Women's Hospital (BWH) and the Harvard-MIT Division of Health Sciences and Technology has demonstrated a better way to deliver cancer drugs directly to tumors by using specially engineered nanoparticles that can inhibit a signaling pathway and deliver a higher concentration of medication to the specific area. Details of their work appear on April 20, in an early online edition of the Proceedings of the National Academy of Science.

Boston, MA (Vocus) April 20, 2009 -- An interdisciplinary team of researchers at Brigham and Women's Hospital (BWH) and the Harvard-MIT Division of Health Sciences and Technology has demonstrated a better way to deliver cancer drugs directly to tumors by using specially engineered nanoparticles that can inhibit a signaling pathway and deliver a higher concentration of medication to the specific area. Details of their work appear on April 20, in an early online edition of the Proceedings of the National Academy of Science.

The team constructed the nanoparticles from a biodegradable, biocompatable, Food and Drug Administration-approved polymer which they chemically engineered to deliver a MAPK inhibitor. By inhibiting the MAPK signaling pathway, which is involved in a majority of human tumors, the nanoparticles hinder the multiplication of cancerous cells and predispose those cells to the cytotoxic effects of chemotherapeutic drugs. The team also modified the polymer to increase drug loading 20 fold, which overcomes a current drawback in nanomedicine, low efficiency of drug loading.

"Current chemotherapeutic drugs must be administered in high concentration throughout the body in order to destroy tumor cells, translating to high toxicity and discomfort for the patient, mainly due to the effects on normal cells," said Rania Harfouche, one lead author of the study, and fellow in the Health Sciences and Technology (HST) Division at BWH. These newly engineered nanoparticles would, however, selectively target the tumor cells and predispose them to chemotherapeutic drugs. "This will allow for lower drug concentration to be used, and provide opportunity for more potent treatments with lesser side-effects for the patient."

The combination of nanoparticles and the cancer drug cisplatin proved successful in preventing the growth of cancerous skin and lung cells and also induced cell death. When researchers gave the same combination to mice with melanoma, it inhibited tumor growth and enhanced the efficacy of the cancer drug. The entire tumors regressed in fifty percent of mice, compared with none in the group receiving cisplatin and the inhibitor without nanoparticles.

In previous work, the group demonstrated that a combination of two drugs delivered with a nanoparticle could exert superior anti-cancer effects. However, most cancers converge into a few pathways for survival and uncontrolled division. "We thought a better strategy might be to target these pathways using nanoparticles, almost like shutting the escape route before exposing the cancer to the drugs," said lead author Sudipta Basu, fellow in the HST Division at BWH.

"The nanoparticles target pathways involved in multiple cancer types and can be applied to a diverse set of cancers, including hard-to-treat cancers, such as breast, pancreatic and liver cancer," noted senior study author Shiladitya Sengupta, PhD, of the Department of Medicine at BWH. "The potential to add homing beacons on the surface of the nanoparticles can increase the efficiency of selectively targeting specific tumors and abolish off target side-effects".

The team also included BWH research fellows Dr. Shivani Soni, Dr. Geetanjali Chimote, and Dr. Raghunath Mashelkar, a polymer chemist and visiting professor at HST from the National Chemical Laboratories in India. This research was funded by grants from the Coulter Foundation, the Mary Kay Ash Charitable Foundation and the Department of Defense BCRP.

Brigham and Women's Hospital (BWH) is a 777-bed nonprofit teaching affiliate of Harvard Medical School and a founding member of Partners HealthCare, an integrated health care delivery network. In July of 2008, the hospital opened the Carl J. and Ruth Shapiro Cardiovascular Center, the most advanced center of its kind. BWH is committed to excellence in patient care with expertise in virtually every specialty of medicine and surgery. The BWH medical preeminence dates back to 1832, and today that rich history in clinical care is coupled with its national leadership in quality improvement and patient safety initiatives and its dedication to educating and training the next generation of health care professionals. Through investigation and discovery conducted at its Biomedical Research Institute (BRI), BWH is an international leader in basic, clinical and translational research on human diseases, involving more than 860 physician-investigators and renowned biomedical scientists and faculty supported by more than $416 M in funding. BWH is also home to major landmark epidemiologic population studies, including the Nurses' and Physicians' Health Studies and the Women's Health Initiative. For more information about BWH, please visit www.brighamandwomens.org.

Contact:
Holly Brown-Ayers
617.534.1603

# # #

Read the full story at http://www.prweb.com/releases/BWH/cancer_drugs/prweb2332424.htm.


'/>"/>
Source: PRWeb
Copyright©2009 Vocus, Inc.
All rights reserved

Related medicine news :

1. Lilly and Partners In Health, Brigham and Womens Hospital Team Up to Fight MDR-TB in Former Soviet Republics
2. Brigham and Womens Researchers Partner with Vocantas to use CallAssure in Clinical Research Study
3. Brigham and Womens Hospital Selects SinglePointe(TM) Automated Patient-Specific Medication Management Solution from Omnicell
4. Brigham and Associates and Insurance Recovery Group Launch Impairment Resources, a Joint Venture to Address Impairment Ratings
5. Combined Insurance Reports that Single Working Women's Week is a Good Time for Annual Review of Insurance Coverage
6. Kabul Under Virtual Lockdown for International Travelers, Progress Still Evident for Women's Programs
7. Easing Social Anxiety During the Holidays: Tips from Harvard Women's Health Watch
8. Jill Bolte Taylor Keynotes ATSU Women's Wellness Luncheon
9. Singapore Premier Women's Hospital Offers Contactless Surgery for Uterine Fibroids
10. Women's Health Services Announces New Associate
11. New research explores newborn in-hospital weight loss
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/25/2016)... ... ... of Bruton Memorial Library on June 21 due to a possible lice infestation, as reported ... head lice: the parasite’s ability to live away from a human host, and to infest ... in the event that lice have simply gotten out of control. , As lice are ...
(Date:6/25/2016)... ... ... On Friday, June 10, Van Mitchell, Secretary of the Maryland Department of Health ... of their exemplary accomplishments in worksite health promotion. , The Wellness at Work Awards ... at the BWI Marriott in Linthicum Heights. iHire was one of 42 businesses to ...
(Date:6/24/2016)... ... June 24, 2016 , ... Marcy was in a crisis. Her son James, eight, was out ... family verbally and physically. , “When something upset him, he couldn’t control his emotions,” remembers ... would throw rocks at my other children and say he was going to kill them. ...
(Date:6/24/2016)... (PRWEB) , ... June 24, 2016 , ... Topical BioMedics, Inc, makers of Topricin and ... that call for a minimum wage raise to $12 an hour by 2020 and then ... will restore the lost value of the minimum wage, assure the wage floor does not ...
(Date:6/24/2016)... ... June 24, 2016 , ... Strategic Capital Partners, ... economy by obtaining investment capital for emerging technology companies. SCP has delivered ... already resulted in more than a million dollars of capital investment for five ...
Breaking Medicine News(10 mins):
(Date:6/23/2016)... Ill. , June 23, 2016  In a startling report ... are failing their residents by lacking a comprehensive, proven plan to ... a definitive ranking of how states are tackling the worst ... to only four states – Kentucky , ... Vermont . Of the 28 failing states, three ...
(Date:6/23/2016)... DUBLIN , June 23, 2016 ... "Key Pharma News Issue 52" report to their offering. ... need in influenza treatment creates a favourable commercial environment for ... and growing patient base that will serve to drive considerable ... flu vaccine would serve to cap sales considerably, but development ...
(Date:6/23/2016)... , June 23, 2016  Astellas today announced the establishment of Astellas Farma Colombia (AFC), a new affiliate ... in Latin America . ... ... ... ...
Breaking Medicine Technology: